despit
intens
studi
mechan
aso
action
mrna
still
incomplet
understood
current
concept
suggest
major
mechan
action
phosphorothio
aso
activ
endonucleas
rnase
h
aso
bind
mrna
result
mrna
degrad
prevent
translat
specif
protein
aso
bind
mrna
also
prevent
assembl
ribosom
complex
eg
via
steric
block
inhibit
rna
splice
figur
phosphorothio
backbon
modif
repres
replac
nonbridg
oxygen
sulfur
atom
phosphoru
figur
modif
commonli
refer
firstgener
greatli
increas
resist
nucleas
howev
render
undesir
biolog
activ
aso
unrel
antisens
properti
see
section
sever
antisens
formul
methyloligonucleotid
morpholino
peptid
nucleic
acid
lock
nucleic
acid
ribozym
recent
small
interf
si
rna
develop
improv
stabil
nucleas
increas
bind
affin
mrna
howev
drawback
low
cell
penetr
lack
rnase
h
recruit
despit
new
gener
aso
disadvantag
signific
thu
phosphorothioatemodifi
aso
still
commonli
use
sinc
discoveri
natur
phenomenon
rna
interfer
rnai
intens
studi
much
enthusiasm
potenti
new
power
therapeut
tool
specif
inhibit
gene
express
rnai
part
innat
antivir
defens
lower
eukaryot
induc
doublestrand
ds
rna
process
nucleotid
sirna
figur
rnai
result
degrad
homolog
endogen
mrna
complementari
antisens
strand
sirna
although
transfect
mammalian
cell
dsrna
induc
strong
interferon
ifn
like
respons
eventu
lead
apoptosi
treatment
sirna
initi
rnai
without
caus
cell
death
sirna
promis
therapi
genet
diseas
sinc
sirna
target
singl
nucleotid
polymorph
thu
specif
target
select
oncogen
recent
studi
demonstr
sirna
could
select
silenc
diseaseassoci
allel
bear
singl
mismatch
howev
clinic
applic
sirna
still
problemat
fulli
understand
mechan
rnai
action
higher
eukaryot
exampl
exogen
appli
sirna
may
interfer
endogen
rnai
pathway
induc
potenti
danger
offtarget
effect
addit
difficult
ensur
effici
deliveri
cellular
uptak
sirna
compar
aso
doublestrand
sirna
bind
plasma
protein
rapidli
degrad
tissu
environ
although
publish
report
sirna
use
vivo
model
lung
diseas
limit
respiratori
syncyti
viru
rsv
parainfluenza
viru
piv
infect
sirnabas
approach
inhibit
oncogen
express
proinflammatori
molecul
profibrot
target
lung
diseas
develop
correct
target
select
critic
develop
asobas
therapi
respiratori
diseas
target
molecul
must
import
diseas
pathogenesi
aso
extrem
potent
essenti
ensur
lung
diseas
specificityselect
target
avoid
potenti
advers
effect
clinic
relev
target
protein
select
specif
aso
critic
issu
must
inhibit
express
target
gene
gene
similar
sequenc
ie
target
mrna
sequenc
homolog
gene
design
aso
genom
care
check
possibl
hybrid
aso
sequenc
nontarget
gene
sequenc
common
sever
molecul
famili
domain
express
mani
gene
must
avoid
selfcomplementari
region
four
contigu
guanin
residu
region
rich
guanin
may
form
complex
aso
secondari
structur
prevent
effici
watsoncrick
hybrid
target
mrna
avoid
presenc
immunostimulatori
cytosineguanin
phosphatelink
dinucleotid
cpg
motif
within
aso
normal
undesir
stimul
tolllik
receptor
tlr
sever
cell
type
howev
instanc
may
includ
addit
benefici
effect
immun
system
vitro
control
aso
specif
nonsens
mismatch
oligonucleotid
sequenc
import
assess
specif
hybrid
select
target
sequenc
ensur
deliveri
aso
target
cell
cation
liposom
often
use
complex
aso
intern
pinocytosisendocytosi
liposom
deliveri
system
extens
use
intraven
local
applic
aso
airway
upon
system
applic
cancer
therapi
asoliposom
complex
preferenti
enter
tumor
tissu
increas
permeabl
blood
vessel
tumor
howev
role
cation
lipid
aso
deliveri
limit
carrier
function
complex
dna
oligonucleotid
cation
lipid
greatli
enhanc
immunostimulatori
properti
dna
properti
provid
addit
therapeut
effect
exampl
cancer
howev
system
releas
high
level
proinflammatori
cytokin
tumor
necrosi
factor
tnf
interleukin
il
well
activ
natur
killer
nk
cell
follow
applic
dnacation
lipid
complex
induc
advers
effect
novel
cation
cardiolipin
analogbas
liposom
appear
less
toxic
effect
transfect
dna
sirna
vitro
vivo
compar
commerci
avail
dotap
base
liposom
recent
year
new
carrier
polyethylenimin
pei
develop
enhanc
effici
aso
deliveri
target
cell
vitro
vivo
despit
enhanc
deliveri
airway
epitheli
cell
pei
toxic
detriment
lung
function
new
strategi
use
chitosandna
nanospher
intranas
deliveri
dna
recent
show
advantag
lipid
cation
carrier
nanospher
protect
dna
nucleas
degrad
multipl
compound
incorpor
nanospher
achiev
addit
effect
howev
deliveri
system
never
assess
antisens
treatment
requir
studi
given
carrierrel
advers
effect
attract
method
aso
deliveri
lung
involv
use
natur
surfact
cation
properti
sever
studi
local
aso
applic
airway
reli
surfact
rather
use
artifici
carrier
system
recent
studi
singl
instil
sirna
mix
surfact
elastas
decreas
express
target
protein
mous
lung
day
examin
pharmacokinet
toxicolog
phosphorothio
modifi
aso
intens
studi
effect
dose
aso
vivo
applic
depend
effici
deliveri
system
mode
administr
system
versu
local
follow
system
applic
phosphorothio
oligonucleotid
bind
plasma
protein
ensur
prolong
effect
variou
aso
dose
system
intraven
subcutan
applic
human
care
evalu
sever
anticanc
therapi
trial
signific
toxic
observ
clinic
relev
dose
pharmacokinet
properti
aerosol
aso
studi
sever
anim
model
follow
aso
deliveri
lung
limit
system
distribut
detect
local
deliveri
aso
airway
allow
administr
lower
dose
compar
intraven
therapi
lung
diseas
studi
phosphorothio
aso
type
adenosin
receptor
singl
effect
inhal
dose
durat
effect
lung
day
studi
aso
spleen
tyrosin
kinas
syk
nebul
enclos
chamber
three
consecut
day
prior
allergen
challeng
precis
dose
rat
receiv
determin
exposur
suppress
antigeninduc
airway
inflamm
follow
hour
exampl
demonstr
effect
aso
dose
durat
effect
depend
target
characterist
addit
import
effici
deliveri
system
quantiti
halflif
target
mrna
encod
protein
critic
determin
aso
pharmacokinet
pharmacodynam
vivo
applic
advers
effect
aso
therapi
tabl
result
hybrid
aso
nonspecif
sequenc
mrna
rather
target
sequenc
assess
express
target
gene
mrna
protein
level
follow
aso
treatment
import
confirm
specif
aso
effect
upon
dnarna
duplex
format
endonucleas
rnase
h
recruit
degrad
rna
duplex
result
recruit
may
nonspecif
activ
rnase
h
result
irrelev
cleavag
effect
express
gene
potenti
sourc
nonsequencespecif
effect
aso
backbon
modif
oligonucleotid
phosphorothioatemodifi
oligonucleotid
bind
famili
heparinbind
protein
includ
growth
factor
receptor
extracellular
matrix
protein
adhes
molecul
mechan
least
partial
explain
advers
effect
system
aso
applic
thrombocytopenia
hypotens
protein
bind
due
polyanion
natur
oligonucleotid
also
respons
abil
activ
complement
outlin
section
immunostimulatori
cpg
motif
aso
sequenc
also
import
sourc
advers
effect
relat
system
cytokin
releas
fatigu
fever
flulik
syndrom
sirna
also
exert
nontargetrel
biolog
effect
particular
induct
proinflammatori
cytokin
effect
relat
abil
dsrna
bind
tlr
present
immun
cell
induc
cellular
activ
must
care
assess
sequenc
use
local
deliveri
aso
offer
advantag
system
intraven
applic
allow
lower
dose
use
thu
minim
system
toxic
import
consider
use
aso
airway
adenosin
releas
oligonucleotid
degrad
product
activ
adenosin
receptor
induc
bronchoconstrict
adenosin
receptor
upregul
certain
clinic
condit
particularli
asthma
target
studi
aso
treatment
experiment
asthma
see
section
anoth
sourc
potenti
advers
effect
relat
aso
deliveri
system
discuss
section
enhanc
immunostimulatori
properti
aso
appli
cation
liposom
complex
may
releas
proinflammatori
cytokin
cation
liposom
may
affect
cellular
function
directli
eg
inhibit
tnfinduc
endotheli
vascular
cell
adhes
express
cytotox
cation
liposom
dosedepend
requir
care
evalu
liposom
use
tyrosin
kinas
syk
mediat
earli
signal
event
import
pathophysiolog
allerg
asthma
initi
crosslink
high
affin
receptor
ige
mast
cell
basophil
bp
aso
direct
syk
gene
construct
stemloop
structur
contain
three
phosphorothio
modif
deliv
aerosol
vivo
use
syk
asoliposom
complex
combin
cation
liposom
dotap
neutral
carrier
lipid
dioleoylphosphatidylethanolamin
dope
treatment
rat
nebul
syk
asoliposom
complex
inhibit
syk
mrna
protein
express
alveolar
macrophag
studi
effect
aerosol
syk
asoliposom
complex
two
model
infecti
model
airway
inflamm
induc
helminth
nippostrongylu
brasiliensi
ii
igemedi
allerg
inflamm
induc
ovalbumin
sensit
brown
norway
rat
model
allerg
asthma
syk
aso
significantli
inhibit
inflammatori
cell
infiltr
airway
lung
eosinophilia
rise
tnf
bronchoalveolar
lavag
induc
antigen
challeng
syk
aso
also
suppress
antigeninduc
tracheal
contract
also
aerosol
sirna
syk
rat
ovalbumininduc
asthma
obtain
promis
downregul
inflamm
unpublish
observ
thu
aerosol
syk
aso
inhibit
mani
central
compon
allerg
asthma
inflamm
although
syk
promis
molecular
target
aso
therapi
asthma
inflammatori
condit
acut
lung
injuri
studi
need
assess
potenti
risk
relat
syk
inhibit
exampl
recent
studi
implic
syk
tumor
suppressor
gene
breast
gastric
cancer
addit
establish
syk
abundantli
express
lung
epitheli
cell
involv
product
proinflammatori
molecul
thu
syk
aso
may
advantag
shortterm
local
therapi
sever
lung
condit
eg
acut
respiratori
distress
syndrom
longterm
applic
syk
aso
rais
potenti
safeti
issu
must
assess
anoth
signal
molecul
potenti
target
aso
therapi
asthma
lyn
srcfamili
kinas
lyn
phosphoryl
occur
immedi
result
conform
chang
cytoplasm
domain
allergenmedi
crosslink
lyn
interact
syk
induc
activ
eosinophil
lyn
associ
receptor
subunit
import
differenti
bone
marrow
stem
cell
vitro
studi
demonstr
aso
direct
lyn
block
eosinophil
differenti
stem
cell
although
lyn
aso
never
appli
experiment
model
asthma
import
lyn
eosinophil
differenti
vivo
confirm
lyn
knockout
mice
recent
studi
allerg
asthma
attempt
inhibit
intracellular
pathway
involv
inflammatori
cell
activ
inhal
aso
mitogenactiv
protein
kinas
downregul
ovalbumininduc
pulmonari
eosinophilia
mucu
hypersecret
airway
hyperrespons
ahr
murin
model
asthma
aso
subunit
transcript
factor
rela
regul
express
proinflammatori
gene
appli
intraven
significantli
inhibit
allerg
respons
mous
model
despit
proof
principl
studi
system
applic
aso
seem
feasibl
treatment
asthma
given
crucial
involv
transcript
factor
regul
immun
respons
given
import
role
helper
type
cytokin
receptor
allerg
asthma
target
aso
therapi
exampl
aso
appli
intraven
murin
model
asthma
inhibit
eosinophilia
ahr
allakhverdi
colleagu
use
intratrach
inject
aso
common
chain
granulocytemacrophag
colonystimul
factor
gmcsf
receptor
demonstr
signific
reduct
eosinophilia
ahr
rat
model
asthma
move
forward
clinic
test
intranas
applic
aso
stem
cell
factor
kit
ligand
kitlg
essenti
develop
mast
cell
decreas
lung
inflamm
murin
model
asthma
aso
transcript
factor
essenti
develop
respons
also
reduc
lung
inflamm
ahr
recent
studi
signal
transduc
activ
transcript
stat
target
use
intranas
applic
decoy
oligonucleotid
mous
model
ovalbumininduc
asthma
studi
demonstr
inhibit
antigeninduc
airway
inflamm
hyperreact
directli
target
bronchial
smooth
muscl
contract
asthma
aso
develop
administ
aerosol
form
rabbit
signific
reduct
bronchoconstrict
airway
inflamm
asobas
therapi
current
phase
ii
clinic
trial
aso
appli
phosphorothioatemodifi
oligonucleotid
liposom
deliveri
system
nake
dna
howev
altern
approach
recent
develop
includ
adenoviralmedi
express
aso
mrna
chlorid
channel
bronchial
epithelium
ovalbuminsensit
mice
approach
decreas
ahr
mucu
product
use
recombin
adenoviru
aso
deliveri
target
cell
offer
advantag
method
select
airway
epithelium
prolong
express
transfect
gene
week
follow
instil
howev
adenovirusmedi
gene
deliveri
induc
immun
respons
adenoviru
preclud
repeat
applic
sever
safeti
concern
potenti
oncogen
transform
importantli
anim
model
asthma
aso
variou
target
molecul
appli
prior
antigen
challeng
whether
asomedi
target
molecul
involv
asthma
pathogenesi
also
effici
ongo
allerg
inflamm
requir
studi
recent
ribozym
target
human
receptor
chain
also
known
develop
approach
offer
advantag
tradit
antisens
mechan
action
ribozym
reli
activ
rnase
p
ubiquit
present
cell
construct
recycl
induc
complementari
mrna
cleavag
therefor
appear
act
effici
dnabas
antisens
anoth
recent
studi
use
sirna
silenc
gene
express
transcript
regul
cytokin
vitroappli
sirna
downregul
protein
express
well
eotaxin
product
human
bronchial
epitheli
cell
studi
genet
asthma
identifi
sever
potenti
asthma
suscept
gene
inflammatori
mediat
disintegrin
metalloproteas
domain
g
proteincoupl
receptor
asthma
suscept
gpra
may
new
target
antisens
therapi
although
biochem
mechan
link
mani
candid
gene
asthma
pathogenesi
poorli
understood
aso
strategi
may
help
elucid
pathway
lung
cancer
mani
oncogen
identifi
studi
target
antisens
therapi
sever
asobas
drug
reach
phase
trial
anticip
soon
approv
clinic
use
see
stahel
zangemeisterwittk
review
particular
antiapoptot
protein
promis
target
aso
therapi
nonsmal
cell
lung
cancer
aso
direct
gene
induc
apoptosi
cancer
cell
potenti
effect
chemotherapi
molecular
target
aso
therapi
lung
cancer
includ
signal
transduct
molecul
protein
kinas
prkca
regulatori
subunit
protein
kinas
raf
kinas
protein
encod
hra
oncogen
numer
preclin
studi
focus
target
regul
apoptosi
cell
cycl
progress
angiogenesi
metastasi
apoptosi
suppressor
survivin
cytochrom
c
oxidas
assembl
protein
sever
growth
factor
receptor
receptor
tyrosin
kinas
well
transcript
factor
asobas
drug
clinic
trial
lung
cancer
short
oligonucleotid
sequenc
phosphorothio
backbon
modif
recent
lock
nucleic
acidmodifi
oligonucleotid
bispecif
activ
bclxl
anoth
antiapoptot
bcl
protein
develop
show
enhanc
antitumor
activ
cancer
cell
sinc
human
cancer
cell
line
preserv
rnai
machineri
use
sirna
silenc
oncogen
involv
cancer
pathogenesi
suggest
inde
sirna
sphase
kinaseassoci
protein
molecul
involv
cell
cycl
regul
overexpress
variou
cancer
includ
smallcel
lung
carcinoma
appli
use
lentivir
adenovir
vector
strategi
significantli
inhibit
tumor
growth
vitro
vivo
although
sever
vitro
studi
use
sirna
variou
target
molecul
potenti
import
tumorigenesi
sirnabas
strategi
requir
investig
regard
effici
effect
potenti
advers
effect
infus
intraven
aso
prepar
show
moder
dosedepend
system
toxic
thrombocytopenia
flulik
syndrom
hypotens
asthenia
clinic
trial
asobas
therapeut
combin
chemotherapeut
agent
strategi
also
need
extens
studi
unfortun
publish
report
local
applic
aso
lung
cancer
antisens
strategi
intend
specif
cleav
genom
rna
rsv
recent
develop
applic
aso
link
tetraadenyl
shown
recruit
cellular
nucleas
rnasel
success
inhibit
rsv
replic
importantli
combin
subtherapeut
dose
aso
antivir
drug
ribavirin
demonstr
potent
inhibitori
effect
recent
studi
describ
use
sirna
rsv
vivo
mice
treat
intranas
sirna
nanoparticl
rsv
protein
infect
rsv
show
substanti
decreas
viru
titer
lung
decreas
inflamm
airway
hyperreact
compar
control
anim
inhibit
rsv
piv
follow
intranas
instil
sirna
mous
also
demonstr
addit
recent
vitro
studi
show
abil
sirna
inhibit
replic
newli
discov
coronaviru
sarscov
caus
agent
sever
acut
respiratori
syndrom
sar
begin
potenti
import
research
area
opportun
develop
innov
aso
therapi
infecti
diseas
lung
tabl
ii
aso
promis
therapeut
tool
variou
respiratori
diseas
rang
infect
asthma
lung
cancer
fibrosi
acut
respiratori
distress
syndrom
major
advantag
aso
convent
drug
capac
specif
block
synthesi
diseaseassoci
protein
thu
prevent
particip
pathogenesi
aso
highli
potent
specif
therefor
essenti
correct
molecular
target
identifi
therapi
appli
aso
complex
heterogen
diseas
asthma
present
major
challeng
sinc
condit
involv
sever
pathway
numer
gene
poorli
understood
geneenviron
interact
approach
specif
target
critic
molecul
asthma
success
develop
asobas
drug
clinic
applic
anticip
near
futur
genet
asthma
rapidli
develop
field
import
discoveri
suscept
gene
import
gene
target
antisens
therapi
may
provid
import
contribut
treatment
common
diseas
aso
therapi
also
potenti
becom
power
tool
lung
cancer
success
anticip
base
intens
molecular
studi
discoveri
causal
oncogen
lung
cancer
base
publish
observ
target
deliveri
aso
lung
feasibl
signific
advantag
system
applic
minim
therapeut
dose
thu
reduc
system
advers
effect
sever
critic
challeng
develop
asobas
therapeut
addit
select
correct
target
protein
specif
aso
effect
essenti
inhibit
gene
must
avoid
sequencespecif
eg
cpgmediat
sequencenonspecif
phosphorothioatemedi
advers
effect
care
assess
new
formul
aso
sirna
promis
therapeut
applic
requir
studi
mechan
action
safeti
new
methodolog
deliveri
aso
select
target
cell
optim
carrier
system
like
provid
import
advanc
therapeut
use
aso
